Systematic review of the benefits and risks ofmetformin in treating obesity in children aged 18 years and younger

Marian McDonagh, Shelley Selph, Alp Ozpinar, Carolyn Foley

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

IMPORTANCE Childhood obesity is an important public health problem with increasing prevalence. Because treatment often has limited success, new approaches must be identified. OBJECTIVE To evaluate the effectiveness and safety ofmetformin for treating obesity in children aged 18 years and younger without a diagnosis of diabetes mellitus. EVIDENCE REVIEW We included randomized clinical trials identified through searches of MEDLINE, the Cochrane Library, and ClinicalTrials.gov. Our primary outcome measure was change in body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).We assessed study quality, pooled data using a random-effects model, and performed subgroup and sensitivity analyses. FINDINGS Fourteen randomized clinical trials were eligible. For BMI, moderate-strength evidence indicated a reduction of -1.38 (95%CI, -1.93 to -0.82) from baseline compared with control at 6 months. A similar, if less dramatic, effect was observed in studies less than 6 months, but the pooled estimate from studies of 1 year of treatment was not statistically significant. Subgroup analyses indicated smaller, but significant, effects for those with baseline BMI below 35, those of Hispanic ethnicity, those with acanthosis nigricans, those who had tried and failed diet and exercise programs, and in studies with more girls or higher mean age (adolescents). Moderate-strength evidence indicated that with metformin, 26%reported a gastrointestinal event compared with 13%in control groups (relative risk, 2.05; 95%CI, 1.19- 3.54), although there was no difference in discontinuations due to adverse events. No serious adverse events were reported. CONCLUSIONS AND RELEVANCE Metformin provides a statistically significant, but very modest reduction in BMI when combined with lifestyle interventions over the short term. A large trial is needed to determine the benefits to subgroups or impacts of confounders. In the context of other options for treating childhood obesity, metformin has not been shown to be clinically superior.

Original languageEnglish (US)
Pages (from-to)178-184
Number of pages7
JournalJAMA Pediatrics
Volume168
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Pediatric Obesity
Metformin
Randomized Controlled Trials
Acanthosis Nigricans
Hispanic Americans
MEDLINE
Libraries
Life Style
Diabetes Mellitus
Body Mass Index
Public Health
Outcome Assessment (Health Care)
Exercise
Diet
Safety
Weights and Measures
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Systematic review of the benefits and risks ofmetformin in treating obesity in children aged 18 years and younger. / McDonagh, Marian; Selph, Shelley; Ozpinar, Alp; Foley, Carolyn.

In: JAMA Pediatrics, Vol. 168, No. 2, 02.2014, p. 178-184.

Research output: Contribution to journalArticle

@article{eeaaeecc371344bcaa39d8424aca3a3e,
title = "Systematic review of the benefits and risks ofmetformin in treating obesity in children aged 18 years and younger",
abstract = "IMPORTANCE Childhood obesity is an important public health problem with increasing prevalence. Because treatment often has limited success, new approaches must be identified. OBJECTIVE To evaluate the effectiveness and safety ofmetformin for treating obesity in children aged 18 years and younger without a diagnosis of diabetes mellitus. EVIDENCE REVIEW We included randomized clinical trials identified through searches of MEDLINE, the Cochrane Library, and ClinicalTrials.gov. Our primary outcome measure was change in body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).We assessed study quality, pooled data using a random-effects model, and performed subgroup and sensitivity analyses. FINDINGS Fourteen randomized clinical trials were eligible. For BMI, moderate-strength evidence indicated a reduction of -1.38 (95{\%}CI, -1.93 to -0.82) from baseline compared with control at 6 months. A similar, if less dramatic, effect was observed in studies less than 6 months, but the pooled estimate from studies of 1 year of treatment was not statistically significant. Subgroup analyses indicated smaller, but significant, effects for those with baseline BMI below 35, those of Hispanic ethnicity, those with acanthosis nigricans, those who had tried and failed diet and exercise programs, and in studies with more girls or higher mean age (adolescents). Moderate-strength evidence indicated that with metformin, 26{\%}reported a gastrointestinal event compared with 13{\%}in control groups (relative risk, 2.05; 95{\%}CI, 1.19- 3.54), although there was no difference in discontinuations due to adverse events. No serious adverse events were reported. CONCLUSIONS AND RELEVANCE Metformin provides a statistically significant, but very modest reduction in BMI when combined with lifestyle interventions over the short term. A large trial is needed to determine the benefits to subgroups or impacts of confounders. In the context of other options for treating childhood obesity, metformin has not been shown to be clinically superior.",
author = "Marian McDonagh and Shelley Selph and Alp Ozpinar and Carolyn Foley",
year = "2014",
month = "2",
doi = "10.1001/jamapediatrics.2013.4200",
language = "English (US)",
volume = "168",
pages = "178--184",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Systematic review of the benefits and risks ofmetformin in treating obesity in children aged 18 years and younger

AU - McDonagh, Marian

AU - Selph, Shelley

AU - Ozpinar, Alp

AU - Foley, Carolyn

PY - 2014/2

Y1 - 2014/2

N2 - IMPORTANCE Childhood obesity is an important public health problem with increasing prevalence. Because treatment often has limited success, new approaches must be identified. OBJECTIVE To evaluate the effectiveness and safety ofmetformin for treating obesity in children aged 18 years and younger without a diagnosis of diabetes mellitus. EVIDENCE REVIEW We included randomized clinical trials identified through searches of MEDLINE, the Cochrane Library, and ClinicalTrials.gov. Our primary outcome measure was change in body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).We assessed study quality, pooled data using a random-effects model, and performed subgroup and sensitivity analyses. FINDINGS Fourteen randomized clinical trials were eligible. For BMI, moderate-strength evidence indicated a reduction of -1.38 (95%CI, -1.93 to -0.82) from baseline compared with control at 6 months. A similar, if less dramatic, effect was observed in studies less than 6 months, but the pooled estimate from studies of 1 year of treatment was not statistically significant. Subgroup analyses indicated smaller, but significant, effects for those with baseline BMI below 35, those of Hispanic ethnicity, those with acanthosis nigricans, those who had tried and failed diet and exercise programs, and in studies with more girls or higher mean age (adolescents). Moderate-strength evidence indicated that with metformin, 26%reported a gastrointestinal event compared with 13%in control groups (relative risk, 2.05; 95%CI, 1.19- 3.54), although there was no difference in discontinuations due to adverse events. No serious adverse events were reported. CONCLUSIONS AND RELEVANCE Metformin provides a statistically significant, but very modest reduction in BMI when combined with lifestyle interventions over the short term. A large trial is needed to determine the benefits to subgroups or impacts of confounders. In the context of other options for treating childhood obesity, metformin has not been shown to be clinically superior.

AB - IMPORTANCE Childhood obesity is an important public health problem with increasing prevalence. Because treatment often has limited success, new approaches must be identified. OBJECTIVE To evaluate the effectiveness and safety ofmetformin for treating obesity in children aged 18 years and younger without a diagnosis of diabetes mellitus. EVIDENCE REVIEW We included randomized clinical trials identified through searches of MEDLINE, the Cochrane Library, and ClinicalTrials.gov. Our primary outcome measure was change in body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).We assessed study quality, pooled data using a random-effects model, and performed subgroup and sensitivity analyses. FINDINGS Fourteen randomized clinical trials were eligible. For BMI, moderate-strength evidence indicated a reduction of -1.38 (95%CI, -1.93 to -0.82) from baseline compared with control at 6 months. A similar, if less dramatic, effect was observed in studies less than 6 months, but the pooled estimate from studies of 1 year of treatment was not statistically significant. Subgroup analyses indicated smaller, but significant, effects for those with baseline BMI below 35, those of Hispanic ethnicity, those with acanthosis nigricans, those who had tried and failed diet and exercise programs, and in studies with more girls or higher mean age (adolescents). Moderate-strength evidence indicated that with metformin, 26%reported a gastrointestinal event compared with 13%in control groups (relative risk, 2.05; 95%CI, 1.19- 3.54), although there was no difference in discontinuations due to adverse events. No serious adverse events were reported. CONCLUSIONS AND RELEVANCE Metformin provides a statistically significant, but very modest reduction in BMI when combined with lifestyle interventions over the short term. A large trial is needed to determine the benefits to subgroups or impacts of confounders. In the context of other options for treating childhood obesity, metformin has not been shown to be clinically superior.

UR - http://www.scopus.com/inward/record.url?scp=84893470006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893470006&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2013.4200

DO - 10.1001/jamapediatrics.2013.4200

M3 - Article

VL - 168

SP - 178

EP - 184

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 2

ER -